Press Releases

Date Title and Summary Additional Formats
Toggle Summary Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Receives Positive Opinion from the CHMP in Europe for Appropriate Patients with COPD
LONDON --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for fluticasone
View HTML
Toggle Summary Positive Results from Pioneering Salford Lung Study in Asthma Published in The Lancet, and Presented at European Respiratory Congress
Relvar Ellipta was superior to usual care treatment in improving asthma control for patients in Salford Lung Study. LONDON & BRISBANE, Calif. --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive results from the Salford Lung Study
View HTML
Toggle Summary Innoviva to Participate in Morgan Stanley's Global Healthcare Unplugged Conference on September 12
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present in a fireside chat format discussion at the Morgan Stanley 15th Annual Global Healthcare Conference at the Grand Hyatt Hotel in
View HTML
Toggle Summary Innoviva to Participate in Baird Global Healthcare Conference on September 7
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer and Eric d'Esparbes, the Company's Senior Vice President and Chief Financial Officer will participate in the 2017 Baird Global Healthcare
View HTML
Toggle Summary Innoviva Completes Refinancing of its 9% 2029 Non-Recourse Notes
Closes $250 Million Term B Loan Refinancing plan expected to reduce the associated current cash interest expense by nearly one-half BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (" Innoviva" or the "Company") (NASDAQ: INVA) today announced the closing of a $250 million Term B Loan (the "Term
View HTML
Toggle Summary Innoviva, Inc. Announces Closing of $175 Million Offering of 2.50% Convertible Senior Notes and Exercise of the Initial Purchasers' $17.5 million Over-Allotment Option
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced that it closed its offering of the Company's 2.50% convertible senior notes due 2025 (the "Notes") for gross proceeds of $192.5 million in aggregate principal.
View HTML
Toggle Summary Innoviva, Inc. Prices Offering of $175 Million of 2.50% Convertible Senior Notes
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced the pricing of $175 million aggregate principal amount of the Company's 2.50% convertible senior notes due 2025 (the "Notes"). The Notes will be sold in a private placement to qualified
View HTML
Toggle Summary Innoviva Announces Proposed Offering of $175 Million of Convertible Senior Notes
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced its intention to offer, subject to market conditions and other factors, $175 million aggregate principal amount of convertible senior notes due 2025 (the "Notes") in a private placement
View HTML
Toggle Summary Innoviva Reports Strong Second Quarter 2017 Financial Results
Royalties earned up 73% and net income up 141% compared to second quarter of 2016 Management to host a conference call and webcast today at 5:00 p.m. Eastern time BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the second quarter
View HTML
Toggle Summary GSK Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma on an ICS/LABA Combination
LONDON --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid (ICS) /
View HTML

Copyright Nasdaq. Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.